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Background 
For decades, clinical trials have been the cornerstone of testing and establishing new therapies 
in cancers, including head and neck cancers (HNC). Academic research organizations 
conducting these trials face a constant struggle to accrue patients, both to advance treatment as 
quickly as possible and to minimize the substantial cost of these trials, which is strongly driven 
by their duration. Banding together institutions in national (e.g., the NCTN in the US, and NCRI 
in UK), international (e.g., EORTC in Europe), and global (e.g., GCIG, BIG, and SIOP for 
gynecological, breast, and pediatric cancers, respectively) consortia has been a successful 
strategy to expand patient catchment areas and increase accrual capacity for networks 1. In 
some cases, particularly for rare cancers, this has enabled study of diseases that could not be 
studied by individual groups 2,3. 
A 2015 review of 694 HNC trials listed on clinicaltrials.gov showed a 13.1% early termination 
rate with insufficient accrual being cited as the most common cause for trial closure. A number 
of factors contribute to the difficulty of accruing patients to head and neck cancer trials: low 
global incidence of these cancers, different treatment approaches (surgical vs. non-surgical) 
across different institutions, high rate of comorbidities in this patient population, small number of 
experienced HNC physicians, poor performance status and treatment compliance due to the 
nature of the cancer, high treatment-related toxicity, and lack of patient awareness in clinical 
trials 4. In addition to these factors, a new barrier in HNC trial recruitment is the changing 
landscape of HNC tumor biology.  
Previously, most mucosal squamous cell carcinoma of the head and neck (HNSCC) were 
attributed to tobacco and alcohol use; therefore, past trials included all HNSCC regardless of 
tumor locations or biology. Recent molecular and genomic advances have led to the global 
awareness that HNSCC is a heterogeneous entity that requires more precise clinical trial design 
for individual HNSCC subsets. For example, treatment de-escalation to decrease toxicity is now 
being tested in non-smokers with good prognosis human papillomavirus (HPV)-related 
oropharyngeal cancer (OPC)	5; whereas treatment escalation to improve outcome is being 
studied in smokers with poor prognosis HPV-negative OPC 6.  Similarly, driver mutations are 
noted in small subsets of HNC 7, and trials are now designed to match targeted drugs with 
appropriate aberrant pathways. As clinical trials evolve to adapt to new knowledge in HNC 
biology, the overall pool of eligible patients for each trial becomes smaller, leading to more 
accrual challenges. Consequently, there is an urgent need for more international collaboration 
to facilitate the conduct of clinical trials in rare HNC to bring new therapies to these tumors in a 
timely fashion. 
The viability of academic clinical trials is limited not only by the difficulty of finding enough 
patients to satisfy trial sample size requirements, but the need to implement trials within a finite 
time frame spanning concept development to final analysis and dissemination of results.  A 
study of 419 federally funded phase I-III studies performed in the US cooperative group system 
revealed that more than a third of these studies did not reach minimum projected accrual and 
that there was an inverse relationship between poor accrual and long clinical trial development 
8. Further, an analysis of historical data of phase III trials within this system indicated that failure 
to achieve threshold accrual rates early in the trial strongly predicted failure to ever successfully 
complete the trial 9. Considering these findings, the US NCI established rules to automatically 
flag for closure any trial taking too long to develop 10 or not reaching specified percentages of 
projected accrual at early time points 11. Phase III trials that fail to reach 20% of projected 
accrual at quarter 5/6 after activation will be administratively closed and those achieving 
between 20% and 50% of projected accrual at this point will be given six months to improve 
accrual. Other funders have similarly protected their investments by establishing policies that 
trigger recommendation for early closure based on a poor accrual trend; for example, the 
EORTC will consider closure of phase III trials when observed accrual during quarter 4/5 since 
first patient in is below 50% and/or when accrual during quarter 8/9 is below 80% of expected 
accrual (Vermoken, personnel communication). 
While further international collaboration is a logical strategy to increase the accrual base, 
conducting trials between groups and across borders necessarily brings its own challenges 
including multiple review processes by funding bodies, sourcing and distribution of drug, 
alignment of protocol development and amendment processes, regulatory and ethics approvals 
across jurisdictions, and coordination of pharmacovigilance and data management 12,13.  Given 
the emphasis on accelerating trial development from concept to first patient in, and on hitting 
projected accrual rates early in trials, creating ad hoc networks for individual trials is 
burdensome and risky.  
Rather working ab initio on each trial, the HNCIG was established as a standing body to take on 
these challenges. After preliminary discussions by some people who started the ball rolling 
alongside the ASCO 2014 general meeting, twenty organizations from around the world 
involved in late phase clinical trials came together in Nice, February 2015, during ICHNO to 
establish the Head and Neck Cancer International Group (HNCIG) to coordinate the 
development and contribute to the accrual of practice-changing trials in these cancers. Since 
then, the group has created statutes that define its mission, goals, organization structure, 
membership and initiated collaborative activities. Below are the summaries of the group’s 
information, activities and aspirations.  
 
HNCIG Mission and Goals 
HNCIG is comprised of “international and national Cooperative Research Groups and Sites 
performing clinical trials and meta-analyses in head and neck tumors, which includes but is not 
restricted to those originating from the upper aero-digestive tract”.  The overarching mission of 
HNCIG is “to promote and conduct high quality clinical trials and meta-analyses to improve 
outcomes for patients with head and neck tumor”. This will be achieved through international 
collaboration, a strong sense of common purpose, shared expertise, and mutual respect among 
the members. Therefore, the aims of the groups include the followings: 
 
• Promote international collaboration 
• Promote clinical and translational research 
• Perform studies in rare tumors 
• Stimulate evidence-based medicine 
• Support educational activities 
• Harmonize clinical trials and translational research guidelines 
 
HNCIG Structures 
Members can be any clinical research network or high-accruing single institution performing 
clinical trials and/or meta-analyses in the field of HNC. Members must have a track record of 
conducting, participating or reporting on Phase III trial(s) or large individual meta-analyses. The 
criteria for membership and continued participation are outlined in the statutes 14. In addition, 
statutes include provisions for non-voting partners representing industry, advocacy, or 
government regulatory authorities.  
Figure 1 shows the structure of HNCIG. The board of directors is the decision-making body of 
the HNCIG and is comprised of one representative from each member. The board of directors 
vote on the executive officers (the chair, secretary and treasurer), who manage the day-to-day 
affairs of the group. The statutes also define the role and function of several permanent 
committees shown in Figure 1. 
HNCIG Activities and Aspirations 
Since its formation, HNCIG has formalized the list of full members (Table 1), elected executive 
officers, as well as created the harmonization committee, whose role is to “advance international 
standardization related to head and neck cancer”. Within the harmonization committee are 
subcommittees focusing on consensus development of protocol endpoints, radiation therapy, 
surgical therapy and systemic therapy.  The endpoint subcommittee is collaborating with the 
DATECAN Group 15 to harmonize the definition of each endpoint and to determine the best 
endpoints for HNC trials based on tumor stage and subsite. The radiotherapy subcommittee is 
generating guidelines for clinical target volumes of the primary tumor for the different head and 
neck mucosal tumor sites. In addition, a future goal of this subcommittee is to generate 
consensus of minimum core methodology and dataset for evaluation of radiotherapy quality and 
compliance and documentation of radiotherapy toxicity. Similar remits for establishing surgical 
consensus guidelines and principles have been set for the surgical subcommittee, which will be 
launched soon. 
The HNCIG has also defined what constitutes a HNCIG trial: a late phase HNC clinical 
treatment trial that is open to international collaboration and involves two or more HNCIG 
member groups. Member organizations have been asked to review their current trial portfolios 
for trials that fit these parameters, and to consent to badging appropriate trials with a unique 
HNCIG identifier. Member groups have also been requested to reference the intergroup in 
publications resulting from these trials, either in publication titles or acknowledgments. These 
are listed as HNCIG trials on the website, hnc.intergroup.info 16.Going forward, member 
organizations have been asked to prospectively agree to such badging and publication 
considerations. 
Going forward, the aspiration of HNCIG is to create a harmonized platform for members within 
the group to conduct clinical trials together in subgroups and rare forms of HNC to maximize 
patient accrual and shorten the trial timeline. In addition, the harmonized platform will facilitate 
across trial comparison as well as pooling trial data for meta-analysis. To achieve its mission, 
HNCIG will need to overcome certain logistic barriers that include regulatory directives that differ 
by countries and escalating financial challenges faced by funders such as the U.S. NCI, CRUK, 
and European Commission programs. Regardless, these barriers have been surmounted by the 
Gynecological Cancer Intergroup (GCIG), which has created a successful platform for 
international trial collaboration in GYN malignancies. We believe that HNCIG, with its dedicated 
members, will be just as successful and will accelerate the introduction of much needed novel 
therapies to HNC patients. 
  
 
  
Figure 1: Organizational Chart for the Head and Neck Cancer Intergroup 
Table 1.  Members of HNCIG 17 
 
Organization Type Main Accrual Base 
Canadian Cancer Trials Group (CCTG, formerly NCIC-CTG) Cooperative Group Canada 
Cancer Trials Ireland Cooperative Group Ireland 
Danish Head and Neck Cancer Group (DAHANCA) Cooperative Group Denmark 
ECOG-ACRIN Cooperative Group USA 
European Organisation for the Research and Treatment of 
Cancer (EORTC) 
Cooperative Group European Union 
Fudan University High Accruing Center China 
Gruppo Oncologico del Nord Ovest (GONO) Cooperative Group Italy 
Groupe d’Oncologie Radiothérapie Tête Et Cou (GORTEC) Cooperative Group France 
Hellenic Cooperative Oncology Group (HeCOG) Cooperative Group Greece 
Hong Kong Nasopharyngeal Carcinoma Study Group Cooperative Group Hong Kong 
Interdisziplinäre Arbeitsgruppe Kopf-Hals-Tumoren der 
Deutschen Krebsgesellschaft (IAG KHT) 
Cooperative Group Germany 
Japanese Clinical Oncology Group (JCOG) Cooperative Group Japan 
* MACH-NC Collaborative Group (Meta-Analyses of 
Chemotherapy in Head and Neck Cancer, Institut Gustav 
Roussy) 
Meta-Analysis Group Global 
National Cancer Research Infrastructure, UK (NCRI) Cooperative Group UK 
National Cancer Centre, Singapore Cooperative Group Singapore 
Nederlandse Werkgroep Hoofd-Hals Tumoren (NWHHT) Cooperative Group Netherlands 
NRG Oncology Cooperative Group USA 
Tata Memorial Centre High Accruing Center India 
Taiwan Cooperative Oncology Group (TCOG) Cooperative Group Taiwan 
Trans-Tasman Radiation Oncology Group (TROG) Cooperative Group Oceania 
* MACH-NC is a non-voting member of the HNCIG Board of Directors, as it does not conduct 
clinical trials. 
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